Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial

Journal of Urology

Volumn 149, Issue 1, 1993, Pages 77-82

  Janknegt, R A ^a   Abbou, C C ^a   Bartoletti, R ^a   Bernstein Hahn, L ^a   Bracken, B ^a   Brisset, J M ^a   Da Silva, F C ^a   Chisholm, G ^a   Crawford, E D ^a   Debruyne, F M J ^a   Dijkman, G D ^a   Frick, J ^a   Goedhals, L ^a   Knonagel, H ^a   Venner, P M ^a   Paulson, D F ^a   Walsh, P C ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

androgen antagonists; antiandrogens; hormone antagonists; orchiectomy; prostatic neoplasms

Indexed keywords

NILUTAMIDE; PLACEBO; TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE SCINTISCANNING; CANCER HORMONE THERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; ORAL DRUG ADMINISTRATION; ORCHIECTOMY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; VISUAL DISORDER;

EID: 0027457020     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-5347(17)36003-2     Document Type: Article

References (25)

1. Huggins C. Hodges C.V. Studies on prostatic cancer. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res. 1 1941 293
2. Borgmann V. Hardt W. Schmidt-Gollwitzer M. Adenauer H. Nagel R. Sustained suppression of testosterone production by the luteinising-hormone releasing-hormone agonist buserelin in patients with advanced prostate carcinoma. A new therapeutic approach? Lancet 1 1982 1097
3. Harper M.E. Pike A. Peeling W.B. Griffiths K. Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro J. Endocr. 60 1974 117
4. Geller J. Albert J.D. DHT in prostate cancer tissue—a guide to management and therapy Prostate 6 1985 19
5. Huggins C. Scott W.W. Bilateral adrenalectomy in prostatic cancer; clinical features and urinary excretion of 17-ketosteroids and estrogen Ann. Surg. 122 1945 1031
6. Bracci U. Di Silverio F. Present procedures with regard to the use of hormone therapy in case of cancer of the prostate Hormonal Therapy of Prostatic Cancer 1977 Cofese Palermo 177 192
7. Labrie F. Dupont A. Belanger A. Lacoursiere Y. Raynaud J.P. Husson J.M. Gareau J. Fazekas A.T. Sandow J. Monfette G. Edmond J. Houle J.G. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens Prostate 4 1983 579
8. Brisset J.M. Nilutamide (Anandron) in prostatic cancer: review article S. Khoury C. Chatelain G. Murphy L. Denis Urology. Prostate Cancer 1990 FIIS et RGP Paris 381 389
9. Béland G. Elhilali M. Fradet Y. Laroche B. Ramsey E.W. Trachtenberg J. Venner P.M. Total androgen blockade for metastatic cancer of the prostate Amer. J. Clin. Oncol. 11 suppl. 2 1988 S187
10. Moguilewsky M. Fiet J. Tournemine C. Raynaud J.P. Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer J. Steroid Biochem. 24 1986 139
11. Gooren L. Spinder T. Spijkstra J.J. van Kessel H. Smals A. Rao B.R. Hoogslag M. Sex steroids and pulsatile luteinizing hormone release in men. Studies in estrogen-treated agonadal subjects and eugonadal subjects treated with a novel nonsteroidal antiandrogen J. Clin. Endocr. Metab. 64 1987 763
12. Kuhn J.M. Billebaud T. Navratil H. Moulonguet A. Fiet J. Grise P. Louis J.F. Costa P. Husson J.M. Dahan R. Bertagna C. Edelstein R. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide) New Engl. J. Med. 321 1989 413
13. Pendyala L. Creaven P.J. Huben R. Tremblay D. Mouren M. Bertagna C. Clinical pharmacokinetics of a new antiandrogen Anandron (RU 23908) G. Murphy S. Khoury A. Küss C. Chatelain L. Denis Prostate Cancer. Part A: Research, Endocrine Treatment, and Histopathology 1987 Alan R. Liss, Inc. New York 351 363
14. Paulson D.F. Carcinoma of the prostate: the therapeutic dilemma Ann. Rev. Med. 35 1984 341
15. Knönagel H. Bolle J.F. Hering F. Senn E. Hodel T. Neuenschwander H. Biedermann C. Die Therapie des metastasierten Prostatakarzinoms durch Orchiektomie plus Anandron versus Orchiektomie plus Placebo. Erste Ergebnisse einer randomisierten Multizenterstudie Helv. Chir. Acta. 56 1989 343
16. Robinson M.R.G. Denis L. Newling D.W.N. Sylvester R. de Pauw M. EORTC protocol 30853: Orchidectomy versus zoladex plus flutamide in the management of metastatic carcinoma of the prostate. Interim statistical analysis of the side effects of treatment Cancer 66 suppl. 5 1990 1022
17. Crawford E.D. Eisenberger M.A. McLeod D.G. Spaulding J.T. Benson R. Dorr F.A. Blumenstein B.A. Davis M.A. Goodman P.J. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma New Engl. J. Med. 321 1989 419
18. Crawford E.D. Smith J.A. Soloway M.S. Lange P.H. Lynch D.F. Al-Juburi A. Bracken R.B. Hayden N. Bertagna C. A randomized controlled clinical trial of leuprolide and anandron versus leuprolide and placebo for advanced prostate cancer J. Urol. 143 part 2 1990 221A abstract 129
19. Fourcade R.O. Cariou G. Coloby P. Colombel P. Coulange C. Grise P. Mangin P. Soret J.Y. Poterre M. Total androgen blockade in the treatment of advanced prostatic carcinoma: final report of a double blind placebo controlled study using zoladex and flutamide J. Urol. 145 part 2 1991 426A abstract 853
20. Fourcade R.O. Cariou G. Coloby P. Colombel P. Coulange C. Grise P. Mangin P. Soret J.Y. Poterre M. Total androgen blockade with zoladex plus flutamide vs. zoladex alone in advanced prostatic carcinoma: interim report of a multicenter, double-blind, placebo-controlled study Eur. Urol. 18 suppl. 3 1990 45
21. Robinson M.R.G. Newling D.W.W. Sylvester R. de Pauw M. Members of the EORTC-GU Group: A phase III trial comparing orchidectomy versus orchidectomy and cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate EORTC protocol 30805 Proc. Amer. Ass. Cancer Res. 30 1989 309 abstract 1229
22. Lunglmayr G. A multicenter trial comparing the luteinizing hormone releasing hormone analog zoladex, with zoladex plus flutamide in the treatment of advanced prostate cancer Eur. Urol. 18 suppl. 3 1990 28
23. Boccardo F. Decensi A. Guarneri D. Rubagotti A. Oneto F. Martorana G. Giuliani L. Delii Ponti U. Petracco S. Cortellini P. Ziveri M. Ferraris V. Bruttini G.P. Epis R. Comeri G. Gallo G. Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an ongoing PONCAP study Eur. Urol. 18 suppl. 3 1990 48
24. Iversen P. Christensen M.G. Friis E. Hornbøl P. Hvidt V. Iversen H.G. Klarskov P. Kramp T. Lund F. Mogensen P. Pedersen T. Rasmussen F. Rose C. Skaarup P. Wolf H. A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate Cancer 66 suppl. 5 1990 1058
25. Di Silverio F. Serio M. D’Eramo G. Sciarra F. Zoladex vs. zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study Eur. Urol. 18 suppl. 3 1990 54